The Insider, at PharmaGossip, Joins the Party. . . .

And now, that kind gent from across the pond, "The Insider" -- has a piece up on my revelations of last Saturday. . . cool (click the image, at right, for more background here):

. . . .However, at the time, Defendants did not inform the medical community or the investing public, including the Plans’ participants, of VYTORIN’s inefficacy, instead, spending millions of dollars in marketing campaigns. As Harlan Kumholz, a cardiologist at Yale University, had observed in his remarks to Forbes, "By the summer of 2005, [Schering-Plough/Merck’s] marketing division [was] so successful that [VYTORIN was] already a blockbuster drug. There was only downside [to analyzing the results of ENHANCE trial]. . . ."

Thanks, PharmaGosssip!